Bekkering, F.C.

patient interferon hepatitis treatment hepatitis c therapy group decline study response genotype assay dose reduction virus hcv rna ribavirin reduction phase hepatitis c virus chapter change sample clearance 4 weeks kinetic figure slope efficacy month analysis detection model result hepatitis c patients combination hepatology effect negativity serum brouwer jt parameter table cirrhosis effectiveness induction brouwer schalm level production phase slope value infection schalm sw serum hcv rna dynamic difference endoscopy bekkering capsule plasma virion 10 mu panel interferon efficacy hcv rna negativity liver number superquant week 4 genotype 1 amplicor method half-life characteristic hcv genotype 1 measurement testing responder trial relapse